COMP <GO>
EMR vs NVDA // REVENUE GROWTH (YOY)
Emerson Electric Company (NYSE) VS. NVIDIA Corporation (NASDAQ) • 15-METRIC TALLY: EMR 5
— NVDA 10
▲ REVENUE GROWTH (YOY) LEADER: NVDA
LAST: $164.94 (-3.40%) • MKT CAP: $95.24B
revenue-growth
3.00%
LAST: $204.64 (-4.22%) • MKT CAP: $4.93T
revenue-growth
83.38%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EMR VS. NVDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EMR | NVDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.80% | 74.67% | -21.87 | NVDA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.70% | 65.06% | -55.36 | NVDA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 30.9x | 23.2x | +7.69 | NVDA | /valuation <GO> |
| Free Cash Flow Yield | 2.80% | 2.58% | +0.22 | EMR | /fcf-yield <GO> |
| Operating Margin | 15.50% | 65.21% | -49.71 | NVDA | /operating-margins <GO> |
| Net Profit Margin | 12.70% | 63.66% | -50.96 | NVDA | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 3.00% | 83.38% | -80.38 | NVDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.25% | 0.02% | +1.23 | EMR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.80 | 19.52 | -14.72 | NVDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | EMR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 8.10% | 9.01% | -0.91 | EMR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.5 | 35.1 | +21.45 | EMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.34 | 2.04 | -0.70 | NVDA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 38.6x | 17.0x | +21.58 | NVDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $95.24B | $4.93T | -$4.84T | NVDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EMR REV | NVDA REV | EMR GROSS % | NVDA GROSS % | EMR FCF | NVDA FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $215.94B | — | 71.1% | — | $96.68B |
| FY 2025 | $18.02B | $130.50B | 52.8% | 75.0% | $2.67B | $60.85B |
| FY 2024 | $17.49B | $60.92B | 50.8% | 72.7% | $2.91B | $27.02B |
| FY 2023 | $15.16B | $26.97B | 44.0% | 56.9% | -$45.4M | $3.81B |
| FY 2022 | — | $26.91B | — | 64.9% | — | $8.13B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EMR // BETA 1.34
NVDA // BETA 2.04